Categories: News

Universe Pharmaceuticals INC Attends West Lake Forum and Exhibits Upgraded Products

Universe Pharmaceuticals INC

West Lake Forum

Universe Pharmaceuticals INC

Upgraded Products

Ji’an, Jiangxi, China, May 12, 2021 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced the Company attended West Lake Forum – China Pharmaceutical Industry Development Forum (the “Forum”) on April 12, 2021 in Hangzhou, China. The Company also exhibited its upgraded version of Guben Yanling Pill at the Forum.

The West Lake Forum was founded in 2013 and has been held in Hangzhou for eight consecutive years. As an annual event of the healthcare industry in China, and an important platform for cooperation among growing healthcare companies, the Forum has been influential in promoting the cooperation of healthcare companies and the development of China’s overall healthcare industry.

The upgraded packaging of Guben Yanling Pill drew attention from many drugstore chains and pharmaceutical distributors immediately after it was exhibited at the Forum. During the Forum, the Company developed cooperative relations with several regional drugstore chains as well as pharmaceutical distributors across China, which the Company believes will contribute to the further growth of the Company.

Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “After talking to many pharmaceutical distributors during the Forum, we have renewed confident in the importance of the healthcare market for middle-aged and older adults. We believe that by unswervingly focusing on the research and development of healthcare products targeting people in this age group, we will be exposed to further business opportunities and a growing market recognition. We expect to build our brand ‘Bai Nian Dan’ into a leading domestic healthcare brand for middle-aged and older adults.”

About Universe Pharmaceuticals INC

Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information, please contact:

Ascent Investors Relations LLC
Tina Xiao
President
Phone: 917-609-0333
Email: tina.xiao@ascent-ir.com

Attachments

Staff

Recent Posts

HealthArc Joins athenahealth’s Marketplace Program to Streamline Remote Care, Patient Outcomes, and Billing Process

HealthArc's unified remote care management platform integrates with athenahealth'sEHR to automate clinical documentation, enhance patient…

5 hours ago

AI/ML Innovations Inc. Enters Market Awareness Agreement

VICTORIA, BC / ACCESSWIRE / November 27, 2024 / AI/ML Innovations Inc. ("AI/ML" or the…

5 hours ago

Theralase(R) Release’s 3Q2024 Financial Statements

TORONTO, ON / ACCESSWIRE / November 27, 2024 / Theralase® Technologies Inc. (" Theralase® "…

5 hours ago

Top NY Plastic Surgeon Dr. Rubinstein Chosen to Train New Advanced BOTOX(R) Cosmetic Technique for Platysma Bands After FDA Approval

Renowned expert Dr. Rubinstein to train practitioners on new BOTOX® technique for smoother neck contours…

8 hours ago

AAMA Installs Loxie Kistler, EdD, MS, BSN, RN, CMA (AAMA), CHUC, as 2024–2026 Secretary

GRAND RAPIDS, MI / ACCESSWIRE / November 27, 2024 / The American Association of Medical…

8 hours ago